<?xml version="1.0" encoding="UTF-8"?>
<p id="para430">In the subgroup analyses, the benefit of lenalidomide on progression-free survival was seen across most subgroups of patients (
 <xref rid="fig4" ref-type="fig">figure 4A</xref>), including those prespecified (transplantation-eligible and transplantation-ineligible patients and those defined as standard risk, high-risk and ultra-high risk genetics). The only significant heterogeneity was between patients who achieved a complete or very good partial response and those who had a partial or minimal response before maintenance therapy (p
 <sub>heterogeneity</sub>&lt;0Â·0001). Although progression-free survival improved significantly with lenalidomide maintenance in both responders and non-responders, patients with a suboptimal response before maintenance therapy appeared to benefit the most.
</p>
